

Jan Beyer-Westendorf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5738109/publications.pdf>

Version: 2024-02-01

191
papers

11,017
citations

50276

46
h-index

31849

101
g-index

199
all docs

199
docs citations

199
times ranked

9301
citing authors

#	ARTICLE	IF	CITATIONS
1	Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. New England Journal of Medicine, 2014, 370, 1402-1411.	27.0	1,221
2	Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism. Circulation, 2014, 129, 479-486.	1.6	794
3	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine, 2016, 375, 1131-1141.	27.0	692
4	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine, 2019, 380, 1326-1335.	27.0	687
5	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. New England Journal of Medicine, 2017, 376, 1211-1222.	27.0	577
6	American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Advances, 2018, 2, 3198-3225.	5.2	492
7	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncology, The, 2019, 20, e566-e581.	10.7	458
8	Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood, 2014, 124, 955-962.	1.4	363
9	Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. European Heart Journal, 2014, 35, 1888-1896.	2.2	320
10	Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. Journal of the American College of Cardiology, 2017, 69, 1536-1544.	2.8	258
11	Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology, the, 2014, 1, e37-e46.	4.6	244
12	The Changing Landscape for Stroke Prevention in AF. Journal of the American College of Cardiology, 2017, 69, 777-785.	2.8	244
13	Long-term Clinical Outcomes of Splanchnic Vein Thrombosis. JAMA Internal Medicine, 2015, 175, 1474.	5.1	180
14	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematology, the, 2020, 7, e18-e27.	4.6	173
15	Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood, 2016, 127, 1417-1425.	1.4	156
16	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thrombosis and Haemostasis, 2018, 118, 1439-1449.	3.4	154
17	Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace, 2016, 18, 1150-1157.	1.7	132
18	Drug persistence with rivaroxaban therapy in atrial fibrillation patients--results from the Dresden non-interventional oral anticoagulation registry. Europace, 2015, 17, 530-538.	1.7	127

#	ARTICLE	IF	CITATIONS
19	Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1247-1257.	3.4	127
20	Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1874-1882.	3.8	122
21	Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 939-949.	3.4	114
22	Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. <i>Lancet Haematology</i> , 2017, 4, e105-e113.	4.6	112
23	Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. <i>European Heart Journal</i> , 2020, 41, 509-518.	2.2	106
24	Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1713-1720.	1.6	90
25	Guidance for the management of venous thrombosis in unusual sites. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 129-143.	2.1	87
26	Edoxaban for treatment of venous thromboembolism in patients with cancer. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1268-1276.	3.4	79
27	Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. <i>Thrombosis and Haemostasis</i> , 2016, 116, 651-658.	3.4	79
28	Bleeding complications during anticoagulant treatment in patients with cancer. <i>Thrombosis Research</i> , 2014, 133, S49-S55.	1.7	73
29	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. <i>Blood Advances</i> , 2018, 2, 788-796.	5.2	71
30	Safety and Feasibility of a Diagnostic Algorithm Combining Clinical Probability, d-Dimer Testing, and Ultrasonography for Suspected Upper Extremity Deep Venous Thrombosis. <i>Annals of Internal Medicine</i> , 2014, 160, 451.	3.9	62
31	Anticoagulant therapy for splanchnic vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1562-1568.	3.8	60
32	Treatment of venous thromboembolism with rivaroxaban in relation to body weight. <i>Thrombosis and Haemostasis</i> , 2016, 116, 739-746.	3.4	58
33	Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT) – findings from the GerHIT multi-centre registry study. <i>Thrombosis Research</i> , 2014, 134, 29-35.	1.7	57
34	Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e176.	2.5	57
35	Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. <i>Thrombosis Journal</i> , 2014, 12, 25.	2.1	55
36	Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. <i>Lancet Haematology</i> , 2016, 3, e267-e275.	4.6	55

#	ARTICLE	IF	CITATIONS
37	Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. <i>Thrombosis and Haemostasis</i> , 2016, 116, 733-738.	3.4	55
38	Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 267-277.	2.1	54
39	Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series. <i>Lancet Haematology</i> , 2016, 3, e480-e488.	4.6	53
40	Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2636-2648.	2.8	53
41	Rivaroxaban for treatment of pediatric venous thromboembolism. An Einsteinâ€” phase 3 doseâ€”exposureâ€”response evaluation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1672-1685.	3.8	52
42	Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care - results from the Dresden NOAC registry. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 908-917.	2.4	51
43	Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. <i>Lancet Haematology</i> , 2019, 6, e500-e509.	4.6	51
44	SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2021, 121, 982-991.	3.4	50
45	Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2015, 114, 645-650.	3.4	48
46	Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery. <i>Thrombosis and Haemostasis</i> , 2013, 109, 154-163.	3.4	47
47	Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses. <i>Thrombosis Research</i> , 2016, 144, 62-68.	1.7	47
48	Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. <i>International Journal of Cardiology</i> , 2017, 227, 261-266.	1.7	47
49	Successful treatment of acute portal vein thrombosis with rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2013, 110, 626-627.	3.4	44
50	Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. <i>Clinical Research in Cardiology</i> , 2019, 108, 772-778.	3.3	44
51	Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 533-535.	2.1	42
52	Benefitâ€”risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2015, 113, 231-246.	3.4	40
53	Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 099-105.	2.7	39
54	Rivaroxaban real-world evidence: Validating safety and effectiveness in clinical practice. <i>Thrombosis and Haemostasis</i> , 2016, 116, S13-S23.	3.4	39

#	ARTICLE	IF	CITATIONS
55	Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2016, 116, 191-197.	3.4	38
56	Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study. <i>Lancet Haematology</i> , 2020, 7, e884-e891.	4.6	38
57	Vaginal bleeding and heavy menstrual bleeding during direct oral anti-Xa inhibitor therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1234-1236.	3.4	32
58	Management and outcome of gastrointestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs. <i>Journal of Gastroenterology</i> , 2017, 52, 1211-1220.	5.1	31
59	Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 169-178.	2.1	31
60	Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial. <i>Thrombosis and Haemostasis</i> , 2020, 120, 132-140.	3.4	30
61	Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with nonvalvular atrial fibrillation and type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2107-2114.	4.4	29
62	Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. <i>Current Medical Research and Opinion</i> , 2020, 36, 1081-1088.	1.9	29
63	Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. <i>Internal and Emergency Medicine</i> , 2018, 13, 1051-1058.	2.0	25
64	Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care. <i>Stroke</i> , 2022, 53, 532-543.	2.0	25
65	Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE. <i>Chest</i> , 2016, 150, 1059-1068.	0.8	24
66	Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. <i>Oncologist</i> , 2018, 23, 822-839.	3.7	24
67	The CHA2DS2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , 2018, 253, 71-77.	1.7	24
68	Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1325-1332.	1.8	23
69	Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score. <i>Thrombosis and Haemostasis</i> , 2022, 122, 818-829.	3.4	23
70	Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. <i>Critical Care</i> , 2022, 26, .	5.8	23
71	What have we learned from real-world NOAC studies in venous thromboembolism treatment?. <i>Thrombosis Research</i> , 2018, 163, 83-91.	1.7	22
72	Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 223-230.	2.5	22

#	ARTICLE	IF	CITATIONS
73	Safety of venous ultrasound in suspected DVT – still a matter of concern?. Thrombosis and Haemostasis, 2009, 102, 5-6.	3.4	21
74	Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Thrombosis and Haemostasis, 2015, 114, 1076-1084.	3.4	21
75	Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry. International Journal of Cardiology, 2018, 257, 276-282.	1.7	21
76	Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism. American Journal of Medicine, 2018, 131, 933-938.e1.	1.5	21
77	Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in at-risk patient groups: pregnancy, elderly and obese patients. Thrombosis Journal, 2019, 17, 24.	2.1	21
78	Definition of major bleeding: Prognostic classification. Journal of Thrombosis and Haemostasis, 2020, 18, 2852-2860.	3.8	21
79	Direct Oral Anticoagulants and Women. Seminars in Thrombosis and Hemostasis, 2016, 42, 789-797.	2.7	20
80	COSIMO – patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study. Thrombosis Journal, 2018, 16, 21.	2.1	20
81	Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 207-216.	2.3	20
82	Gastrointestinal endoscopy in patients receiving novel direct oral anticoagulants: results from the prospective Dresden NOAC registry. Journal of Gastroenterology, 2018, 53, 236-246.	5.1	19
83	Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data. Journal of Thrombosis and Thrombolysis, 2021, 51, 349-358.	2.1	19
84	Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. Blood Advances, 2022, 6, 3569-3578.	5.2	19
85	Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 575-582.	1.7	18
86	Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs). American Journal of Cardiovascular Drugs, 2015, 15, 235-242.	2.2	17
87	Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. Journal of Thrombosis and Thrombolysis, 2016, 42, 197-204.	2.1	17
88	Risk of bleeding and arterial cardiovascular events in patients with splanchnic vein thrombosis in Denmark: a population-based cohort study. Lancet Haematology, 2018, 5, e441-e449.	4.6	17
89	Mortality in patients with intracerebral hemorrhage associated with antiplatelet agents, oral anticoagulants or no antithrombotic therapy. European Journal of Internal Medicine, 2020, 75, 35-43.	2.2	17
90	Survival and quality of life after early discharge in low-risk pulmonary embolism. European Respiratory Journal, 2021, 57, 2002368.	6.7	17

#	ARTICLE	IF	CITATIONS
91	Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis. Blood Advances, 2022, 6, 4516-4523.	5.2	16
92	A clinical decision rule and D-dimer testing to rule out upper extremity deep vein thrombosis in high-risk patients. Thrombosis Research, 2016, 148, 59-62.	1.7	15
93	Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol. Journal of Thrombosis and Thrombolysis, 2016, 41, 293-300.	2.1	15
94	Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill. Thrombosis Journal, 2019, 17, 6.	2.1	15
95	Outpatient or inpatient treatment for acute pulmonary embolism: a retrospective cohort study of 439 consecutive patients. Journal of Thrombosis and Thrombolysis, 2015, 40, 26-36.	2.1	14
96	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. Thrombosis Research, 2017, 149, 29-37.	1.7	14
97	Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: A propensity-score weighted administrative claims cohort study. Thrombosis Research, 2018, 168, 31-36.	1.7	14
98	Non-vitamin K Antagonist Oral Anticoagulants (NOAC) as an Alternative Treatment Option in Tumor-Related Venous Thromboembolism. Deutsches Ärztblatt International, 2019, 116, 31-38.	0.9	14
99	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. Thrombosis and Haemostasis, 2021, 121, 1097-1106.	3.4	14
100	Patient Preferences Regarding Anticoagulation Therapy in Patients with Cancer Having a VTE Event - a Discrete Choice Experiment in the Cosimo Study. Blood, 2019, 134, 2159-2159.	1.4	14
101	Development of Recommendations to Continue Anticoagulation with One of the Two Types of Oral Anticoagulants Based on the Identification of Patients' Preference. Seminars in Thrombosis and Hemostasis, 2015, 41, 166-177.	2.7	13
102	Hormonal Contraception. Guideline of the DGGG, OEGGG and SGGG (S3 Level, AWMF Registry Number) Tj ETQq0 0 0 rgBT /Qverlock 10	1.8	13
103	Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery â€“ findings from the ORTHOâ€“EP registry. British Journal of Clinical Pharmacology, 2012, 74, 947-958.	2.4	12
104	Clinical history of cancerâ€“associated splanchnic vein thrombosis. Journal of Thrombosis and Haemostasis, 2021, 19, 983-991.	3.8	12
105	Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study). Thrombosis and Haemostasis, 2021, 121, 206-215.	3.4	12
106	Sex hormones and venous thromboembolism â€“ from contraception to hormone replacement therapy. Vasa - European Journal of Vascular Medicine, 2018, 47, 441-450.	1.4	12
107	Severe Hemorrhage Associated With Oral Anticoagulants. Deutsches Ärztblatt International, 2020, 117, 312-319.	0.9	12
108	Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 491-497.	4.9	11

#	ARTICLE	IF	CITATIONS
109	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. <i>Thrombosis Research</i> , 2018, 168, 121-129.	1.7	11
110	DOACS in women: pros and cons. <i>Thrombosis Research</i> , 2019, 181, S19-S22.	1.7	11
111	Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103125.	4.4	11
112	Secondary Immune Thrombocytopenia (ITP) Associated with ChAdOx1 Covid-19 Vaccination – A Case Report. <i>TH Open</i> , 2021, 05, e315-e318.	1.4	11
113	Trousseau's syndrome in a patient with adenocarcinoma of unknown primary and therapy-resistant venous thrombosis treated with dabigatran and fondaparinux. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 715-716.	2.4	10
114	Venous thromboembolism prevention and treatment: expanding the rivaroxaban knowledge base with real-life data. <i>European Heart Journal Supplements</i> , 2015, 17, D32-D41.	0.1	10
115	Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 339-345.	2.1	10
116	Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism – The COSIMO study. <i>Thrombosis Research</i> , 2021, 206, 1-4.	1.7	10
117	International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER). <i>Thrombosis Journal</i> , 2019, 17, 7.	2.1	9
118	Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAME-TT2-R2 Score: An Analysis of Hokusai-VTE. <i>Thrombosis and Haemostasis</i> , 2019, 119, 675-684.	3.4	9
119	Reproductive issues in women on direct oral anticoagulants. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12512.	2.3	9
120	Increase of Gastrointestinal Bleeding With New Oral Anticoagulants: Problems of a Meta-analysis. <i>Gastroenterology</i> , 2013, 145, 1162-1163.	1.3	8
121	Definition of haemostatic effectiveness in interventions used to treat major bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1112-1115.	3.8	8
122	Pharmacokinetics of Direct Oral Anticoagulants in Emergency Situations: Results of the Prospective Observational RADOA-Registry. <i>Thrombosis and Haemostasis</i> , 2022, 122, 552-559.	3.4	8
123	Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state. <i>Thrombosis Research</i> , 2018, 163, 132-137.	1.7	7
124	Betrixaban for prevention of venous thromboembolism in acute medically ill patients. <i>European Heart Journal Supplements</i> , 2018, 20, E16-E22.	0.1	7
125	5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry. <i>Thrombosis Research</i> , 2021, 202, 24-30.	1.7	7
126	Detection of Direct Oral Anticoagulants in Patient Urine Samples by Prototype and Commercial Test Strips for DOACs – A Systematic Review and Meta-analysis. <i>TH Open</i> , 2021, 05, e438-e448.	1.4	7

#	ARTICLE	IF	CITATIONS
127	The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2791-2800.	3.8	7
128	Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC-MS/MS. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 777-787.	2.1	7
129	Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 139.	2.0	6
130	Rationale, design, and methodology of the observational INSIGHTS-SVT study on the current state of care and outcomes of patients with superficial vein thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2017, 5, 553-560.e1.	1.6	6
131	Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 499-506.	3.8	6
132	Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism. <i>European Journal of Haematology</i> , 2019, 102, 143-149.	2.2	6
133	Rates, management and outcome of bleeding complications during edoxaban therapy in daily care – results from the DRESDEN NOAC REGISTRY. <i>Thrombosis Research</i> , 2020, 190, 91-98.	1.7	6
134	Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high- and low-dose rivaroxaban with aspirin. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 308-313.	2.3	6
135	Point of care coagulation management in anesthesiology and critical care. <i>Minerva Anestesiologica</i> , 2022, 88, .	1.0	6
136	Coagulation activation after discontinuation of VTE treatment with different oral anticoagulants and impact on 12-month clinical outcomes. <i>Thrombosis Research</i> , 2015, 136, 261-266.	1.7	5
137	Longitudinal kidney function trajectories predict major bleeding, hospitalization and death in patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , 2019, 282, 47-52.	1.7	5
138	The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation. <i>TH Open</i> , 2021, 05, e353-e362.	1.4	5
139	Predictors of deep venous thrombosis in patients admitted to rehabilitation clinics after major orthopaedic surgery. <i>Vasa - European Journal of Vascular Medicine</i> , 2013, 42, 40-49.	1.4	5
140	Acute Treatment Of Pulmonary Embolism With Rivaroxaban - Real Life Data From The Prospective Dresden Noac Registry (NCT01588119). <i>Blood</i> , 2013, 122, 2380-2380.	1.4	5
141	Stroke prevention in atrial fibrillation: evidence from real-life studies: Table 1. <i>European Heart Journal Supplements</i> , 2015, 17, D42-D52.	0.1	4
142	Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice. <i>Orthopedic Research and Reviews</i> , 2017, Volume 9, 1-11.	1.1	4
143	Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population. <i>Chest</i> , 2018, 154, 1371-1378.	0.8	4
144	The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. <i>Thrombosis Research</i> , 2018, 170, 75-83.	1.7	4

#	ARTICLE	IF	CITATIONS
145	579â€œThe Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Sub-Analysis. American Journal of Gastroenterology, 2019, 114, S332-S333.	0.4	4
146	Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE. American Journal of Medicine, 2019, 132, 498-504.	1.5	4
147	Homoarginine and methylarginines independently predict long-term outcome in patients presenting with suspicion of venous thromboembolism. Scientific Reports, 2021, 11, 9569.	3.3	4
148	Rationale and design of XARENO: XA inhibition in RENal patients with non-valvular atrial fibrillation. Observational registry. Kardiologia Polska, 2021, 79, 1265-1267.	0.6	4
149	First trimester anticoagulant exposure and adverse pregnancy outcomes in women with preconception venous thromboembolism: a nationwide cohort study. American Journal of Medicine, 2021, , .	1.5	4
150	Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962095491.	1.7	3
151	Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12566.	2.3	3
152	Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. Blood, 2012, 120, 499-499.	1.4	3
153	Centrally Adjudicated Cause of Death during Noac Treatment â€œ Results of the Prospective Dresden Noac Registry (NCT01588119). Blood, 2014, 124, 2876-2876.	1.4	3
154	Pattern and Management of ISTH Major Bleeding Complications with Direct Oral Anticoagulants - Results of the Prospective Dresden Noac Registry (NCT01588119). Blood, 2015, 126, 892-892.	1.4	3
155	Treatment of Acute VTE with Rivaroxaban - Results of the Prospective Dresden Noac Registry (NCT01588119). Blood, 2016, 128, 2618-2618.	1.4	3
156	Rivaroxaban Versus Fondaparinux in the Treatment of Superficial Vein Thrombosis - the Surprise Trial. Blood, 2016, 128, 85-85.	1.4	3
157	Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: The Improve-VTE Study. Blood, 2018, 132, 1241-1241.	1.4	3
158	Cancerâ€œAssociated ThrOmboSis â€œ Patientâ€œReported OutcoMes With RivaRoxaban (COSIMO) â€œ Baseline characteristics and clinical outcomes. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12604.	2.3	3
159	Intracranial bleeding under vitamin K antagonists or direct oral anticoagulants: results of the RADOA registry. Neurological Research and Practice, 2022, 4, 16.	2.0	3
160	Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY. Thrombosis Research, 2022, 215, 37-40.	1.7	3
161	Small clots with large impact. Blood, 2015, 126, 926-927.	1.4	2
162	Deep Vein Thrombosis â€œ Current Management Strategies. Clinical Medicine Insights Therapeutics, 2016, 8, CMT.S18890.	0.4	2

#	ARTICLE	IF	CITATIONS
163	Diagnosis and Treatment of Pulmonary Embolism in Challenging Populations. Hamostaseologie, 2018, 38, 87-97.	1.9	2
164	Anticoagulation with direct factor Xa inhibitors in transplant recipients: Results from the DRESDEN NOAC REGISTRY (NCT01588119). Thrombosis Research, 2020, 191, 50-55.	1.7	2
165	Safety and Feasibility of a Diagnostic Algorithm Combining Clinical Probability, D-Dimer and Ultrasonography in Suspected Upper Extremity Deep Vein Thrombosis: A Prospective Management Study. Blood, 2012, 120, 391-391.	1.4	2
166	Baseline Characteristics and Clinical Outcomes from the Cancer Associated Thrombosis - Patient Reported Outcomes with Rivaroxaban (COSIMO) Trial. Blood, 2019, 134, 2161-2161.	1.4	2
167	Cancer in males and risk of venous thromboembolism. Thrombosis Research, 2010, 125, S155-S159.	1.7	1
168	Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study. Haematologica, 2019, 104, e474-e477.	3.5	1
169	Systematic Literature Review of Randomized Trials Comparing Antithrombotic Therapy Following Revascularization Procedures in Patients With Peripheral Artery Disease. Angiology, 2020, 71, 773-790.	1.8	1
170	Direct Oral Anticoagulants in Atrial Fibrillation: Practical Considerations and Remaining Issues. Hamostaseologie, 2021, 41, 035-041.	1.9	1
171	Checkpoint inhibitors and thrombosis: what's up?. Blood, 2021, 137, 1569-1570.	1.4	1
172	Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry. TH Open, 2021, 05, e143-e151.	1.4	1
173	Every 6 seconds in Europe. Thrombosis Research, 2021, , .	1.7	1
174	Edoxaban dosing patterns in real life practice – Results from the DRESDEN NOAC REGISTRY. Thrombosis Update, 2021, 5, 100070.	0.9	1
175	Drug Persistence with Rivaroxaban Therapy in Atrial Fibrillation Patients Results from the Dresden NOAC registry. Blood, 2014, 124, 4264-4264.	1.4	1
176	Pattern and Management of Vaginal Bleeding Complications, Especially Hypermenorrhea, with Direct Oral Anticoagulants - Results of the Prospective Dresden Noac Registry (NCT01588119). Blood, 2015, 126, 1131-1131.	1.4	1
177	Continued commitment to safety: building on the existing rivaroxaban knowledge base: Table 1. European Heart Journal Supplements, 2015, 17, D21-D28.	0.1	0
178	Letter to the Editor – Gender related aspects of bleeding with rivaroxaban in venous thromboembolism – Potential for pitfalls. Thrombosis Research, 2016, 148, 152-153.	1.7	0
179	Independent data about the safety and efficacy of rivaroxaban for prevention of stroke/embolism are needed: Author reply. Europace, 2016, 18, 156.2-158.	1.7	0
180	Evaluation of direct oral anticoagulants in superficial-vein thrombosis – Authors' reply. Lancet Haematology, 2017, 4, e254-e255.	4.6	0

#	ARTICLE	IF	CITATIONS
181	Response to the Letter by Lucijanic et al., regarding our manuscript "Management and outcome of gastro-intestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs" Journal of Gastroenterology, 2017, 52, 1077-1078.	5.1	0
182	Reply: Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in the management of major bleeding: Methodological issues. Journal of Thrombosis and Haemostasis, 2019, 17, 1398-1399.	3.8	0
183	Efficacy and Safety of VTE Prophylaxis with Oral Rivaroxaban Compared to Fondaparinux or Low-Molecular Weight Heparin In a Large Cohort of Consecutive Patients Undergoing Major Orthopaedic Surgery. Blood, 2011, 118, 210-210.	1.4	0
184	Hospitalization or Outpatient Treatment for Acute Pulmonary Embolism - a Retrospective Cohort Study of 439 Consecutive Patients with Community-Acquired Pulmonary Embolism. Blood, 2012, 120, 3416-3416.	1.4	0
185	Antithrombotic Treatment and Outcomes of Splanchnic Vein Thrombosis in an International Prospective Registry: Results of 2-Year Follow-up. Blood, 2014, 124, 592-592.	1.4	0
186	Localization, Management, Resource Consumption and Outcome of Major Gastrointestinal Bleeding in Patients with Direct Oral Anticoagulants, Vka and Antiplatelet Therapy. Blood, 2016, 128, 141-141.	1.4	0
187	NOAC Therapy Is Also Effective and Safe in Patients Older Than 80 Years " Results of the Prospective Dresden NOAC Registry (NCT01588119). Blood, 2018, 132, 422-422.	1.4	0
188	In Reply. Deutsches Ärztblatt International, 2019, 116, 420-421.	0.9	0
189	Patterns of VTE Treatment with Noac in Cancer Patients - Results of the Prospective Dresden Noac Registry (NCT01588119). Blood, 2019, 134, 3667-3667.	1.4	0
190	Hokusai post-PE study: a follow-up study on long-term outcomes of pulmonary embolism in patients treated with edoxaban vs warfarin. , 2020, , .		0
191	Long-term VTE treatment with rivaroxaban: Results from the DRESDEN NOAC REGISTRY. Thrombosis Research, 2021, 208, 181-189.	1.7	0